Baseline demographics and disease characteristics by age infused set
| . | All patients (N = 768) . | ≥18 years (n = 233) . | <18 years (n = 535) . | <3 years (n = 58) . |
|---|---|---|---|---|
| Median age at infusion (range), y | 13.8 (0.4-25.9) | 21.8 (18.0-25.9) | 10.6 (0.4-17.9) | 1.6 (0.4-2.9) |
| Male sex | 459 (59.8) | 144 (61.8) | 315 (58.9) | 29 (50.0) |
| Race | ||||
| White | 542 (70.6) | 171 (73.4) | 371 (69.3) | 37 (63.8) |
| African-American | 43 (5.6) | 14 (6.0) | 29 (5.4) | 9 (15.5) |
| Asian | 26 (3.4) | 4 (1.7) | 22 (4.1) | 2 (3.4) |
| American Indian or Alaskan Native | 5 (0.7) | 1 (0.4) | 4 (0.7) | 0 |
| Other | 30 (3.9) | 6 (2.6) | 24 (4.5) | 4 (6.9) |
| Unknown | 75 (9.8) | 21 (9.0) | 54 (10.1) | 4 (6.9) |
| Not reported | 47 (6.1) | 16 (6.9) | 31 (5.8) | 2 (3.4) |
| Ethnicity | ||||
| Hispanic or Latino | 304 (39.6) | 118 (50.6) | 186 (34.8) | 12 (20.7) |
| Non-Hispanic or Latino | 383 (49.9) | 100 (42.9) | 283 (52.9) | 41 (70.7) |
| Nonresident of the United States | 55 (7.2) | 9 (3.9) | 46 (8.6) | 2 (3.4) |
| Unknown | 26 (3.4) | 6 (2.6) | 20 (3.7) | 3 (5.2) |
| Karnofsky/Lansky score of <80 | 106 (13.8) | 40 (17.2) | 66 (12.3) | 3 (5.2) |
| DS | 47 (6.1) | 7 (3.0) | 40 (7.5) | 0 |
| Cytogenetics | ||||
| Abnormal 11q23/KMT2A rearrangement | 110 (14.3) | 23 (9.9) | 87 (16.3) | 44 (75.9) |
| Ph+ | 46 (6.0) | 19 (8.2) | 27 (5.0) | 0 |
| Previous systemic therapy | ||||
| Median previous lines of therapy (range), n | 4 (1-19) | 4 (1-15) | 4 (1-19) | 3 (1-13) |
| Chemotherapy | 622 (81.0) | 182 (78.1) | 440 (82.2) | 51 (87.9) |
| Tyrosine kinase inhibitors∗ | 80 (10.4) | 32 (13.7) | 48 (9.0) | 0 |
| allo-SCT | 195 (25.4) | 61 (26.2)† | 134 (25.0) | 12 (20.7) |
| CAR T-cell therapy | 16 (2.1) | 6 (2.6) | 10 (1.9) | 0 |
| Blinatumomab | 142 (18.5) | 62 (26.6) | 80 (15.0) | 7 (12.1) |
| Inotuzumab | 71 (9.2) | 39 (16.7) | 32 (6.0) | 4 (6.9) |
| Rituximab | 22 (2.9) | 16 (6.9) | 6 (1.1) | 0 |
| Other | 172 (22.4) | 61 (26.2) | 111 (20.7) | 14 (24.1) |
| Most recent disease status before infusion | ||||
| Primary refractory‡ | 94 (12.2) | 29 (12.4) | 65 (12.1) | 9 (15.5) |
| First relapse | 205 (26.7) | 62 (26.6) | 143 (26.7) | 26 (44.8) |
| Second relapse | 139 (18.1) | 45 (19.3) | 94 (17.6) | 5 (8.6) |
| Third or later relapse | 56 (7.3) | 26 (11.2) | 30 (5.6) | 2 (3.4) |
| Morphologic CR‡ | 271 (35.3) | 71 (30.5) | 200 (37.4) | 16 (27.6) |
| MRD negative | 163 (60.1) | 44 (62.0) | 119 (59.5) | 11 (68.8) |
| MRD positive | 100 (36.9) | 25 (35.2) | 75 (37.5) | 5 (31.3) |
| Not reported or not tested | 9 (3.3) | 2 (2.8) | 7 (3.5) | 0 |
| BMB percentage before infusion | ||||
| 0 | 181 (23.6) | 48 (20.6) | 133 (24.9) | 14 (24.1) |
| >0 to <5% | 155 (20.2) | 47 (20.2) | 108 (20.2) | 8 (13.8) |
| ≥5% to <50% | 128 (16.7) | 34 (14.6) | 94 (17.6) | 12 (20.7) |
| ≥50% | 103 (13.4) | 41 (17.6) | 62 (11.6) | 8 (13.8) |
| Not reported | 201 (26.2) | 63 (27.0) | 138 (25.8) | 16 (27.6) |
| Extramedullary disease before infusion | ||||
| No | 561 (73.0) | 163 (70.0) | 398 (74.4) | 37 (63.8) |
| Yes | 114 (14.8) | 42 (18.0) | 72 (13.5) | 16 (27.6) |
| Isolated CNS disease | 71 (9.2) | 25 (10.7) | 46 (8.6) | 11 (19.0) |
| . | All patients (N = 768) . | ≥18 years (n = 233) . | <18 years (n = 535) . | <3 years (n = 58) . |
|---|---|---|---|---|
| Median age at infusion (range), y | 13.8 (0.4-25.9) | 21.8 (18.0-25.9) | 10.6 (0.4-17.9) | 1.6 (0.4-2.9) |
| Male sex | 459 (59.8) | 144 (61.8) | 315 (58.9) | 29 (50.0) |
| Race | ||||
| White | 542 (70.6) | 171 (73.4) | 371 (69.3) | 37 (63.8) |
| African-American | 43 (5.6) | 14 (6.0) | 29 (5.4) | 9 (15.5) |
| Asian | 26 (3.4) | 4 (1.7) | 22 (4.1) | 2 (3.4) |
| American Indian or Alaskan Native | 5 (0.7) | 1 (0.4) | 4 (0.7) | 0 |
| Other | 30 (3.9) | 6 (2.6) | 24 (4.5) | 4 (6.9) |
| Unknown | 75 (9.8) | 21 (9.0) | 54 (10.1) | 4 (6.9) |
| Not reported | 47 (6.1) | 16 (6.9) | 31 (5.8) | 2 (3.4) |
| Ethnicity | ||||
| Hispanic or Latino | 304 (39.6) | 118 (50.6) | 186 (34.8) | 12 (20.7) |
| Non-Hispanic or Latino | 383 (49.9) | 100 (42.9) | 283 (52.9) | 41 (70.7) |
| Nonresident of the United States | 55 (7.2) | 9 (3.9) | 46 (8.6) | 2 (3.4) |
| Unknown | 26 (3.4) | 6 (2.6) | 20 (3.7) | 3 (5.2) |
| Karnofsky/Lansky score of <80 | 106 (13.8) | 40 (17.2) | 66 (12.3) | 3 (5.2) |
| DS | 47 (6.1) | 7 (3.0) | 40 (7.5) | 0 |
| Cytogenetics | ||||
| Abnormal 11q23/KMT2A rearrangement | 110 (14.3) | 23 (9.9) | 87 (16.3) | 44 (75.9) |
| Ph+ | 46 (6.0) | 19 (8.2) | 27 (5.0) | 0 |
| Previous systemic therapy | ||||
| Median previous lines of therapy (range), n | 4 (1-19) | 4 (1-15) | 4 (1-19) | 3 (1-13) |
| Chemotherapy | 622 (81.0) | 182 (78.1) | 440 (82.2) | 51 (87.9) |
| Tyrosine kinase inhibitors∗ | 80 (10.4) | 32 (13.7) | 48 (9.0) | 0 |
| allo-SCT | 195 (25.4) | 61 (26.2)† | 134 (25.0) | 12 (20.7) |
| CAR T-cell therapy | 16 (2.1) | 6 (2.6) | 10 (1.9) | 0 |
| Blinatumomab | 142 (18.5) | 62 (26.6) | 80 (15.0) | 7 (12.1) |
| Inotuzumab | 71 (9.2) | 39 (16.7) | 32 (6.0) | 4 (6.9) |
| Rituximab | 22 (2.9) | 16 (6.9) | 6 (1.1) | 0 |
| Other | 172 (22.4) | 61 (26.2) | 111 (20.7) | 14 (24.1) |
| Most recent disease status before infusion | ||||
| Primary refractory‡ | 94 (12.2) | 29 (12.4) | 65 (12.1) | 9 (15.5) |
| First relapse | 205 (26.7) | 62 (26.6) | 143 (26.7) | 26 (44.8) |
| Second relapse | 139 (18.1) | 45 (19.3) | 94 (17.6) | 5 (8.6) |
| Third or later relapse | 56 (7.3) | 26 (11.2) | 30 (5.6) | 2 (3.4) |
| Morphologic CR‡ | 271 (35.3) | 71 (30.5) | 200 (37.4) | 16 (27.6) |
| MRD negative | 163 (60.1) | 44 (62.0) | 119 (59.5) | 11 (68.8) |
| MRD positive | 100 (36.9) | 25 (35.2) | 75 (37.5) | 5 (31.3) |
| Not reported or not tested | 9 (3.3) | 2 (2.8) | 7 (3.5) | 0 |
| BMB percentage before infusion | ||||
| 0 | 181 (23.6) | 48 (20.6) | 133 (24.9) | 14 (24.1) |
| >0 to <5% | 155 (20.2) | 47 (20.2) | 108 (20.2) | 8 (13.8) |
| ≥5% to <50% | 128 (16.7) | 34 (14.6) | 94 (17.6) | 12 (20.7) |
| ≥50% | 103 (13.4) | 41 (17.6) | 62 (11.6) | 8 (13.8) |
| Not reported | 201 (26.2) | 63 (27.0) | 138 (25.8) | 16 (27.6) |
| Extramedullary disease before infusion | ||||
| No | 561 (73.0) | 163 (70.0) | 398 (74.4) | 37 (63.8) |
| Yes | 114 (14.8) | 42 (18.0) | 72 (13.5) | 16 (27.6) |
| Isolated CNS disease | 71 (9.2) | 25 (10.7) | 46 (8.6) | 11 (19.0) |
Data are reported as n (%), unless otherwise specified.
Ph+, Philadelphia chromosome positive.
Includes dasatinib, imatinib, ponatinib, and nilotinib.
One patient aged >18 years received an autologous SCT.
Disease status was defined by response to CIBMTR Comprehensive Report Form 2402 R3.0 Question 147: primary refractory was classified as primary induction failure, and morphologic CR included first, second, or third or later CR.